Aetna is taking aim at one of oncology's biggest administrative headaches: the mountain of prior authorization paperwork that cancer patients and their care teams face. The insurer is now bundling all preapprovals for cancer care — including chemotherapy, immunotherapy, radiation oncology, and associated imaging like MRIs and CT scans — into a single upfront request. The program went live for Medicaid members in eight states (Oklahoma, Illinois, Maryland, New Jersey, Virginia, Florida, Kentucky, and West Virginia) on September 1, with a full rollout to Medicare Advantage and commercial plans planned for the first half of 2027.

Previously, providers were submitting an average of four separate prior authorizations per Aetna cancer patient over the course of treatment. The bundled approach lets oncologists make evolving care decisions without repeatedly seeking new approvals, keeping the focus on patients rather than paperwork.

By the Numbers:

• 4 — average prior auth submissions per Aetna cancer patient before the change
• ~25% — share of eligible members who have already had auths bundled under the pilot
• 74% of providers cite administrative burden as the top challenge for clinical staff
• 31% say prior authorization is the single largest contributor to that burden
• 8 Medicaid states currently live; Medicare + commercial expansion in H1 2027

Why it matters: Prior authorization delays in cancer care can directly affect patient outcomes. By consolidating approvals upfront, Aetna's move could meaningfully reduce treatment lag times and provider burnout — and it's part of a broader industry shift, with UnitedHealthcare and Humana also pledging significant cuts to their prior auth requirements.